MATERIALS & CONSUMABLE GOODSNo sanctions match · screened 20 Nov 2026

Pfizer

pfizer.comUpdated 8 Nov 2026

Strategic intent

Pfizer is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative medicines, vaccines, and oncology therapies.

Key market signals

  • 2026-11: Appointed Cecile Guegan as permanent Chief Financial Officer and Executive Vice President, effective November 1, 2026.
  • 2026-11: Raised full-year 2026 revenue guidance to $62.0B - $64.0B, driven by strong commercial execution of launched and acquired products.
  • 2026-11: Appointed James Tornos as Chief Procurement Officer and VP of Global Procurement, succeeding Sirsij Peshin.
  • 2026-07: Promoted Dennis Hancock to Chief Information Officer and EVP to lead enterprise-wide technology, digital, and AI strategy.
  • 2026-06: Reached a global settlement in principle to resolve the federal Depo-Provera brain tumor multidistrict litigation (MDL-3140).

Financial health

  • Reported Q3 2026 revenues of $16.583 billion, representing a flat year-over-year performance on an operational basis (https://www.pfizer.com)
  • Reported Q3 2026 net income of $3.242 billion, down 8% from $3.541 billion in the prior-year quarter (https://www.pfizer.com)
  • Raised full-year 2026 revenue guidance to a range of $62.0 billion to $64.0 billion (midpoint $63.0 billion) and adjusted diluted EPS guidance to $2.95 to $3.05 (https://www.pfizer.com)

Impact & compliance

SBTi CommittedSocial ImpactModern Slavery Statement (2025)Scope 3 data: comprehensiveThird-party assured

Forensic audit

  • Jul 2026: In July 2026, Pfizer reached a $44 million class action settlement to resolve allegations that it manufactured and sold Chantix tablets containing undisclosed, elevated levels of N-nitroso-varenicline, a probable human carcinogen.
  • Jun 2026: On June 15, 2026, Pfizer reached a global settlement in principle in the Depo-Provera meningioma multi-district litigation (MDL 3140) to resolve claims of women alleging injuries from the drug, following a surge to over 5,500 pending cases.
  • Apr 2026: In April 2026, the Alabama Court of Civil Appeals affirmed a trial court judgment denying Pfizer's corporate income tax …
More findings — log in

Proprietary analysis

  • Strategic fit

    AI-calculated strategic alignment score

    Log in to see
  • Cultural fit

    Trust and integrity score

    Log in to see
  • Alignment dimensions

    How this supplier scores against each of your strategic imperatives

    Log in to see
  • Full forensic analysis

    Complete ESG audit, modern slavery risk assessment, labour sentiment analysis, and observed contradictions with evidence trails.

    Log in to see

Want the full analysis?

Strategic and cultural fit scoring, full forensic detail and alignment dimensions, for this supplier and your own.